Pro-Pharmaceuticals to commercialise cancer drug
Kuwait: Wednesday, April 09 - 2008 at 08:27
US-based Pro-Pharmaceuticals, a company developing targeted therapeutic compounds to treat serious disease, has announced that it has signed a letter of intent with Yiaco Medical Co of Kuwait for the commercialisation of Davanat for the treatment of colorectal and biliary cancer. Yiaco Medical serves 18 countries and represents 80 healthcare companies in the Middle East and North Africa. Davanat is a proprietary carbohydrate polymer. Davanat's mechanism of action is based upon binding to lectins on the diseased cell surface. It targets specific lectin receptors (Galectins) that are over-expressed on cancer cells.
- ADD ARTICLE TO
-
Facebook
del.icio.us
Digg">
Also consider reading:
- » 1st robotic arm surgery in UAE
- » Qatar only wants healthy beef
- » Paediatrics get CME credit hours
- » Mozarella cancer scare in Qatar
- » Sterilisation for UAE women now legal at private hospitals
- » Aldar to develop Cleveland Clinic Abu Dhabi
- » Qualiphar-Gifrer sets up in Dubai
- » Egyptian woman dies of Blird Flu
- » Arabtec signs medical insurance deal with DNIR
- » Dubai to study health of students
Jeff Florian, Senior ReporterWednesday, April 09 - 2008 at 08:27 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Index : Healthcare
Browse related articles
Browse related articlesToday's most read articles:
Most read articles the past week:
Disclaimer:
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
Web Feeds